about
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationNovel targeted agents for the treatment of lung cancer in ChinaRamucirumab: preclinical research and clinical development.Anti-angiogenic therapies for advanced esophago-gastric cancerAt least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibodyDW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Development of antibody-based c-Met inhibitors for targeted cancer therapy.A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer TherapyChemotherapy for Hepatocellular Carcinoma: Current Evidence and Future PerspectivesAnti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
P2860
Q26765941-4FDB0AA9-B57A-4D14-AC97-155B75C6F82FQ26786580-AF4DE92D-8926-4660-9463-4196043C9568Q34446310-5ECFF676-876D-4B40-B916-0BF229BF9964Q34686222-A88B6B47-C2EF-435F-9C13-63E635F455B7Q36517187-912055A4-F3E3-4A40-B79F-177B0190DBC2Q36644256-FD28A347-4974-464F-9064-5CF0581FC4BEQ37662388-6DDBC9DE-3174-47A4-ADE3-F180BB419A8BQ38473672-B6F2C141-3ED0-43A9-84A9-C8CE383329E7Q38550459-E56D5DDD-FFC7-42B5-A97F-4B843984CCC2Q38852051-9D1CADD3-0D7E-459B-8BD0-E6B471C80C65Q38912279-8AAEAC52-0ACE-4BD2-BCFD-932990864196Q41574359-1CE40140-B11E-48E2-B116-E4649B4610E1Q41706847-F59D0666-D4CA-4B56-84CE-FD4227E07541Q44645655-3D14D927-132C-4FA7-B7E9-A2A6EA372CB4Q58729601-1C627D1C-3347-44EA-9589-166ACB00CB0A
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Ramucirumab: first global approval.
@en
type
label
Ramucirumab: first global approval.
@en
prefLabel
Ramucirumab: first global approval.
@en
P2860
P1433
P1476
Ramucirumab: first global approval.
@en
P2093
Asha Vaidya
Raewyn M Poole
P2860
P2888
P304
P356
10.1007/S40265-014-0244-2
P577
2014-06-01T00:00:00Z
P6179
1035014957